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VHL inactivation is an important pathway for the development
of malignant sporadic pancreatic endocrine tumors
Abstract
A small subset of familial pancreatic endocrine tumors (PET) arises in patients with von Hippel-Lindau
syndrome and these tumors may have an adverse outcome compared to other familial PET. Sporadic
PET rarely harbors somatic VHL mutations, but the chromosomal location of the VHL gene is
frequently deleted in sporadic PET. A subset of sporadic PET shows active hypoxia signals on mRNA
and protein level. To identify the frequency of functionally relevant VHL inactivation in sporadic PET
and to examine a possible prognostic significance we correlated epigenetic and genetic VHL alterations
with hypoxia signals. VHL mutations were absent in all 37 PETs examined. In 2 out of 35 informative
PET (6%) methylation of the VHL promoter region was detected and VHL deletion by fluorescence in
situ hybridization was found in 14 out of 79 PET (18%). Hypoxia inducible factor 1alpha (HIF1-alpha),
carbonic anhydrase 9 (CA-9), and glucose transporter 1 (GLUT-1) protein was expressed in 19, 27, and
30% of the 152 PETs examined. Protein expression of the HIF1-alpha downstream target CA-9
correlated significantly with the expression of CA-9 RNA (P<0.001), VHL RNA (P<0.05), and VHL
deletion (P<0.001) as well as with HIF1-alpha (P<0.005) and GLUT-1 immunohistochemistry
(P<0.001). These PET with VHL alterations and signs of hypoxia signalling were characterized by a
significantly shortened disease-free survival. We conclude that VHL gene impairment by promoter
methylation and VHL deletion in nearly 25% of PET leads to the activation of the HIF-pathway. Our
data suggest that VHL inactivation and consecutive hypoxia signals may be a mechanism for the
development of sporadic PET with an adverse outcome.
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Abstract
A small subset of familial pancreatic endocrine tumors (PET) arises in patients with von
Hippel–Lindau syndrome and these tumors may have an adverse outcome compared to other
familial PET. Sporadic PET rarely harbors somatic VHL mutations, but the chromosomal location
of the VHL gene is frequently deleted in sporadic PET. A subset of sporadic PET shows active
hypoxia signals on mRNA and protein level. To identify the frequency of functionally relevant VHL
inactivation in sporadic PET and to examine a possible prognostic significance we correlated
epigenetic and genetic VHL alterations with hypoxia signals. VHL mutations were absent in all 37
PETs examined. In 2 out of 35 informative PET (6%) methylation of the VHL promoter region was
detected and VHL deletion by fluorescence in situ hybridization was found in 14 out of 79 PET
(18%). Hypoxia inducible factor 1a (HIF1-a), carbonic anhydrase 9 (CA-9), and glucose
transporter 1 (GLUT-1) protein was expressed in 19, 27, and 30% of the 152 PETs examined.
Protein expression of the HIF1-a downstream target CA-9 correlated significantly with the
expression of CA-9 RNA (P!0.001), VHL RNA (P!0.05), and VHL deletion (P!0.001) as well as
with HIF1-a (P!0.005) and GLUT-1 immunohistochemistry (P!0.001). These PET with VHL
alterations and signs of hypoxia signalling were characterized by a significantly shortened
disease-free survival. We conclude that VHL gene impairment by promoter methylation and VHL
deletion in nearly 25% of PET leads to the activation of the HIF-pathway. Our data suggest that
VHL inactivation and consecutive hypoxia signals may be a mechanism for the development of
sporadic PET with an adverse outcome.
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Introduction
The molecular pathogenesis of the sporadic pancreatic
endocrine tumors (PET) is still poorly understood
(Gumbs et al. 2002). Mutations in the MEN1 gene
are the most common finding in hereditary PET
(Chandrasekharappa et al. 1997) and this gene is also
mutated in a subset of sporadic PET (Perren et al.
2007). Patients with the von Hippel–Lindau disease
develop PET in 15% (Lubensky et al. 1998), and these
tumors tend to be malignant (Corcos et al. 2008).
Malignant PET also occur rarely in neurofibromatosis
type 1 (NF1; Perren et al. 2006) and tuberous sclerosis
1 (TSC1; Francalanci et al. 2003) syndromes. On a
functional level, all three genes predisposing to
PET with an increased risk of malignancy, namely
VHL, NF1, and TSC1, are linked to hypoxia
signalling via upregulation of hypoxia inducible factor
1 (HIF1; Brugarolas & Kaelin 2004, Semenza 2007,
Johannessen et al. 2008). The pVHL protein plays
a key role in this regulation: a protein complex
Endocrine-Related Cancer (2009) 16 1219–1227
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including pVHL marks HIF for proteasomal
degradation and loss of pVHL function which leads
to an accumulation of HIF1-a in the nucleus (del Peso
et al. 2003). The resulting activation of HIF responsive
elements leads to the increased transcription of a wide
range of hypoxia-inducible genes, among them
carbonic anhydrase 9 (CA-9) and glucose transporter
1 (GLUT-1; Behrooz & Ismail-Beigi 1999, Zhang
et al. 1999, Semenza 2007). HIF may also be activated
by a loss of function of the NF1 and the TSC1 genes via
activation of mammalian target of rapamycin (mTOR)
(Brugarolas & Kaelin 2004, Dutcher 2004).
In sporadic PET, somatic mutations of the VHL gene
are rare (Chung et al. 1997, Moore et al. 2001) and a
minor role of the VHL gene in the genesis of these
tumors has been deduced from this fact (Lindberg et al.
2007). However, there is evidence that hypoxia
signalling plays an important role in sporadic PET:
expression array data comparing benign and malignant
PET point towards a deregulation of hypoxia-associ-
ated mRNAs (Couvelard et al. 2006). On the genomic
level of sporadic PET we know from comparative
genomic hybridization (CGH) and loss of hetero-
zygosity (LOH) studies that the deletions of 3p, where
the VHL gene is localized, are frequent and are also
associated with an adverse prognosis (Barghorn et al.
2001, Speel et al. 2001). As these 3p deletions often
comprise large parts of the short arm of chromosome 3,
it is unknown whether the loss of the VHL gene or the
other genes is of relevance for tumor development. At
last, hypoxia is a well-known driving force of growth in
several tumors (Brizel et al. 1996, Hockel et al. 1996).
The aim of this study was to investigate if hypoxia
signalling in sporadic PET is associated with genomic
VHL alterations. In order to answer this question,
we analyzed a well-characterized series of sporadic
PET (Schmitt et al. 2007)
a) on DNA level by VHLmutation, deletion, and VHL
promoter methylation analysis
b) on mRNA level by analyzing the expression of the
VHL gene and of hypoxia-associated target genes
c) on protein level by determining the expression of
the hypoxia target proteins HIF1-a, CA-9, and
GLUT-1.
Materials and methods
Tumor specimens
Tissue specimens of 152 patients were included in the
study (Schmitt et al. 2007). The available paraffin
specimens comprised 139 primary tumors and 13
metastases. According to the WHO 2004 classification,
51 out of the 139 primary tumors (37%) were well-
differentiated PET (wd PET), 37 tumors (27%) were
well-differentiated PET of uncertain behavior (wd PET
ub), 34 tumors (24%) were well-differentiated pan-
creatic endocrine carcinomas (wd PEC), and 3 tumors
(2%) were poorly-differentiated PEC (pd PEC). In 14
tumors (10%), not all information for the classification
was available. According to the recently proposed
tumor, node, metastasis (TNM) classification (Rindi
et al. 2006) primary tumors were classified as follows:
54 tumors (39%) were classified as T1, 39 tumors
(28%) as T2, 25 tumors (18%) as T3, and 2 tumors
(1%) as T4. In 19 tumors (14%), not all information for
the classification was available.
Fresh frozen tissue of 37 out of the above mentioned
tumor samples (28 primary tumors and 9 metastases)
were available for liquid-based DNA and RNA
analysis. Seven out of these 37 fresh frozen tissue
samples (19%) were classified as wd PET, 13 (35%)
as wd PET ub, 14 (38%) as wd PEC, and 3 (8%) as
pd PEC.
Immunohistochemistry
Sections of 4 mm from a tissue microarray (TMA;
Schmitt et al. 2007) were stained with antibodies
against HIF1-a, CA-9, and GLUT-1. The immuno-
histochemical staining for all antigens was performed
on automated staining systems (GLUT-1 on Ventana
BenchMark, Ventana Medical Systems, Tucson, AZ,
USA and HIF1-a and CA-9 on Bond Refine, Vision
BioSystems Ltd, Newcastle Upon Tyne, UK). The
following antibodies were used: HIF1-a clone mgc3
ab16066 (Abcam, Cambridge, UK), dilution 1:500;
CA-9 polyclonal antibody ab15086 (Abcam), dilution
1:200; GLUT-1 polyclonal antibody AB1341
(Chemicon International, Temecula, CA, USA),
dilution 1:1000. Antigen retrieval was performed by
heating (H2(60) (EDTA-based pH 9.0 Bond Epitope
Retrieval Solution, 60 min), for HIF1-a, H2(30)
(EDTA based pH 9.0 Bond Epitope Retrieval Solution,
30 min) for CA-9 and CC1 mild (Tris based buffer,
30 min) for GLUT-1). Visualization was performed
using the avidin–biotin complex method leading to a
brown staining signal. For HIF1-a glioblastoma tissue
and for both CA-9 and GLUT-1 normal liver tissue was
used as controls.
For all stainings the intensity (negative, weak
positivity, strong positivity) as well as the percentage
of positive tumor cells was recorded.
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VHL deletion analysis
Sections of 7 mmof the TMAwere used for fluorescence
in situ hybridization (FISH) analysis to detect copy
number losses. Deletion analysis was performed by
double-target FISH using a chromosome 3-specific
centromere probe in combination with a 3p25-specific
probe containing the VHL gene. The DNA probes were
labeledwith fluorescein-12-dUTP (spectrum green) and
Alexa-647-aha-dUTP (spectrum red) by nick translation
(Roche) and precipitated in ethanol in the presence of
Cot-1 DNA, sodium acetate, and glycogen. The DNA
pellet was re-suspended in the hybridization buffer
(55% formamide, 10% dextran sulfate). After dehy-
dration in an ethanol series, the slides were denatured in
0.2 M HCl at room temperature for 20 min and in 1 M
NaSCN for 30 min at 80 8C. Proteinase treatment was
performed by incubation in 0.4 g/l pepsin in 10 mM
Tris–HCl solution for 10 or 20 min at 37 8C, followed by
post-fixation in 4% formalin for 10 min at room
temperature. After sequential washings in 2!SSC and
distilledwater and dehydration in an ethanol series, both
probes were applied to the tissue specimens, denatured
at 80 8C for 5 min and then incubated at 37 8C overnight
in a humified chamber. Post-hybridization washes were
performed twice for 5 min at 60 8C in 0.4!SSC and
once for 5 min at room temperature in 4!SSC.
Blocking was performed by incubating the slides
with each 100 ml of a solution of 4!SSC and non-fat-
dried-milk 5% at 37 8C in a humidified chamber for
20 min. After washing the slides in 4!SSC/0.05%
Tween for 5 min, the hybridized fluorescein-labeled
probes were detected using a cascade of rabbit
anti-FITC immunoglobulins (1:1000, Dako, Glostrup,
Denmark), FITC-conjugated swine anti-rabbit immu-
noglobulins (1:100, Dako) and FITC-conjugated rabbit
anti-swine immunoglobulins (1:1000, Dako, Glostrup,
Denmark). The Alexa-647-aha-dUTP-labeled probes
were detected using amouse anti-cyanine 5monoclonal
antibody (1:1000, Kreatech, Amsterdam, The Nether-
lands). The slides were washed in 4!SSC/
0.05% Tween, air-dried and then mounted in Vecta-
shield (Vector, Burlingame, CA, USA) containing
0.5 mg/ml 4 0,6-diamidino-2-phenylindole-antifade
(Sigma) for nuclear counterstaining. Images were
recorded with Analysis software (Olympus
Biosystems, Hamburg, Germany).
VHL mutation analysis
In 37 tumors, mutation analysis for the VHL gene was
performed. DNA from fresh frozen tissue was
extracted using the Purgene-kit (Gentra Systems,
Minneapolis, MN, USA) according to the
manufacturer’s recommendations. Frozen sections
stained by hematoxylin–eosin were used for the
morphological control of tumor tissue quality and
microdissection. PCR using genomic DNA as template
was carried out in a 50 ml mixture of 1!PCR buffer
containing 400 ng of template DNA, 200 mM dNTP
(Roche), 1 mM of each intron-based primer, and 1 ml
Taq Polymerase (Ampli Taq Gold, Perkin Elmer,
Europe, UK). Mutation analysis was performed by
denaturing gradient gel electrophoresis and direct
sequencing of samples with aberrant banding patterns
as described (Anlauf et al. 2006).
Methylation-sensitive PCR
In 35 tumors, a methylation sensitive PCR of the VHL
promoter region was informative. DNA from fresh
frozen tissue was modified by bisulfite treatment
(Qiagen), converting all unmethylated cytosine
residues to uracil. This bisulfite treatment was followed
by amplification with primers specific for methylated
and unmethylated DNA (Table 1). PCR amplification
of template DNA was performed as follows: 99 8C for
5 min, 60 8C for 25 min, 99 8C for 5 min, 60 8C for
85 min, 99 8C for 5 min, 60 8C for 175 min, and a final
extension step of 20 8C for at least 5 min. For each set
of DNA modification and PCR, a cell line of human
kidney cancer with known hypermethylation of the
VHL promoter (769-P) was included as a positive
control. The PCR-products were additionally cycle
sequenced and the methylation status of all the CpG
residues was analyzed to assess the possibility of
incomplete CpG methylation.
RNA analysis
In 32 tumors, high quality RNA could be extracted
from fresh frozen tissue. RNA was analyzed for the
expression of the VHL gene and of the hypoxia-
associated target gene CA-9. RNA from fresh frozen
tissue was extracted using the RNeasy MiniKit
(Qiagen) according to the manufacturer’s recommen-
dations. After extraction, DNAse digestion, NanoDrop
measurement, and quality control via gel electro-
phoresis 1 mg RNA was transcribed into cDNA using
oligo dT primers. Quantitative TaqMan analysis was
Table 1 Primers used for methylation-sensitive PCR
VHL MF 5 0-TGGAGGATTTTTTTGYGTAYGY-30
VHL UF 5 0-GTTGGAGGATTTTTTTGYGTAYGY-30
VHL MR 5 0-RAACCRAACRCCRCRAA-3 0
VHL UR 5 0-CCCRAACCRAACRCCRC-3 0
MF, methylated forward; MR, methylated reverse; UF,
unmethylated forward; UR, unmethylated reverse.
Endocrine-Related Cancer (2009) 16 1219–1227
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performed on a Applied Biosystems 7900HT Fast
Real-Time PCR System using the probes CA-9
(hCG37623) and VHL (hCG1994953; Applied Bio-
systems, Foster City, CA, USA). Data were normalized
using the expression data of normal pancreatic islet
RNA. GAPDH was referred to as a housekeeping gene.
The cut-off for overexpression (CA-9) and under-
expression (VHL RNA) was defined as at least twofold
difference to normal islet RNA respectively.
Statistical analysis
Fisher’s exact test (SPSS software, Chicago, IL, USA)
was used to examine the relationship between the
results obtained from the DNA, RNA, and immuno-
histochemical investigations. Level of significance was
defined as P!0.05.
Ethics
The study was approved by the local ethical committee
(Stv 40-2005).
Results
HIF1-a, CA-9 and GLUT-1 immunohistochemistry
HIF1-a was scored as positive if a nuclear staining was
detected in at least 5% of the tumor cells (Fig. 1).
Twenty-four out of 127 (19%) tumors expressed HIF1-
a. In wd PET, HIF1-a was expressed in 2 out of 33
cases (6%). In wd PET ub, HIF1-a was expressed in
5 out of 37 cases (13.5%), whereas in wd PEC and pd
PEC HIF1-a was expressed in 9 out of 31 (29%) and in
1 out of 3 (33%) primary tumors and in 4 out of 11
(36%) of metastases thereof.
CA-9 was scored as positive if a cytoplasmic
staining was detected in at least 5% of the tumor
cells (Fig. 1). Thirty-six out of 134 (27%) tumors
expressed CA-9. In wd PET, CA-9 was expressed in
only a minority of the tumor cells (5% each) in 2 out of
40 cases (5%). In wd PET ub, CA-9 was expressed in
10 out of 34 cases (29%), whereas in wd PEC and pd
PEC, CA-9 was expressed in 14 out of 32 (44%) and in
1 out of 3 (33%) primary tumors, respectively and in
7 out of 12 (58%) of their metastases.
GLUT-1 was scored as positive if a membranous
and/or cytoplasmic staining was observed in at least
25% of the tumor cells and/or if the staining was
strong (Fig. 1). All tumors with!25% positive tumor
cells showed only a faint intensity and were scored
as negative.
Forty out of 133 (30%) tumors expressed GLUT-1.
In wd PET, GLUT-1 was expressed in 6 out of 40 cases
(15%). In wd PET ub, GLUT-1 was expressed in 12 out
of 34 cases (35%), whereas in wd PEC and pd PEC,
GLUT-1 was expressed in 11 out of 32 (34%) and in
3 out of 3 (100%) primary tumors, respectively and in
6 out of 12 (50%) of their metastases.
Figure 1 A PET (A, H&E) with nuclear positivity for HIF1-a (B), cytoplasmic andmembranous positivity for CA-9 (C), and cytoplasmic
positivity for GLUT-1 (D).
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An example of a PET with immunohistochemical
positivity for HIF1-a, CA-9 and GLUT-1 is shown
in Fig. 1.
DNA analysis
In 78 out of 152 cases (51%), FISH on the TMA was
informative. In 14 out of 78 cases (18%), the deletion
of the VHL gene was detected by FISH (Fig. 2). VHL
deletion was defined as loss of one VHL signal in at
least 20% of tumor cells. The percentage of tumor cells
with a VHL deletion ranged from 20 to 90%.
VHL gene mutations were absent in all 37 tumors
examined.
Methylation of the VHL promoter region was
detected in 2 out of 35 cases (6%; Fig. 3). Sequencing
showed a methylation of all CpG residues in the
amplified promotor region. One of those two cases
correlated with the highest overexpression of CA-9
(sevenfold) RNA observed and with a threefold
underexpression of VHL mRNA. None of the 32
remaining samples showed any methylation including
the methylation of single CpG residues.
Both PET with VHL promoter methylation showed
two 3p signals by FISH.
RNA analysis
VHL RNA was underexpressed by factor 2 or more
compared to normal islets in 8 out of 32 (25%) tumors,
the remaining 24 PET (75%) showed an expression
rate from 0.51- to three-fold. CA-9 RNA was regularly
expressed in 22 out of 32 (69%) and overexpressed in
10 out of 32 (31%) tumors.
Statistical analysis
Results of HIF1-a, CA-9, and GLUT-1 immuno-
histochemistry correlated significantly with each
other (P!0.005 and !0.001 respectively). CA-9
immunohistochemistry correlated significantly with
CA-9 RNA overexpression (P!0.001) and VHL
underexpression (P!0.05). Importantly, a positive
correlation was found between CA-9 immunopositivity
and VHL deletion (P!0.001) and if CA-9 protein
expression was correlated to VHL methylation
and deletion counted as one ‘impaired VHL
function’ group (P!0.001). Moreover, HIF1-a
protein expression correlated significantly with VHL
underexpression (P!0.05). Genomic VHL alteration
Figure 2 FISH shows a deletion of the 3p25 gene locus (red
signal) and of the centromere of chromosome 3 (green signal) in
most of the tumor cells in these two PET.
Figure 3 Sequence analysis of the largest CpG island of the
VHL promoter: a PET without (A) and one of the two PET with
methylation (B). Note that the conversion of cytosine to uracil by
bisulfite treatment in the unmethylated tumor in contrast to the
methylated tumor, in which all cytosine residues are retained.
Endocrine-Related Cancer (2009) 16 1219–1227
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and CA-9 protein expression both correlated with
recurrence and poor survival (Fig. 4). An overview
over the correlation results is given in Table 2 and
further details given in (Supplementary Table 1, which
can be viewed online at http://erc.endocrinology-
journals.org/supplemental/).
Discussion
Somatic VHL mutations are a rare event in sporadic
PET (Chung et al. 1997, Moore et al. 2001). However,
several results from the recent literature suggest that
VHL-associated hypoxia might nevertheless play a
role in sporadic PET (Barghorn et al. 2001, Couvelard
et al. 2005, 2006).
We analyzed a series of sporadic PET on DNA,
RNA, and protein-expression levels to define the role
of VHL and hypoxia. VHL mutations were absent in
all 37 tumors, thus reflecting the low-mutation rate
reported in the literature (Chung et al. 1997, Moore
et al. 2001). In the present study, we extended the
analysis to VHL deletion and promoter methylation.
We found a hypermethylation in the VHL promoter
in 6% of the investigated tumors. CpG island
methylation of the VHL gene leading to gene
silencing is frequent in renal cell carcinoma (Herman
et al. 1994, Glavac et al. 1996, Dulaimi et al. 2004).
CpG island methylation of other genes has been
previously described in a subset of PET (Chan et al.
2003), which was associated with an adverse
outcome (Arnold et al. 2007). VHL methylation has
not yet been reported in PET. We found VHL gene
deletion in 14 out of 78 tumors (18%) by FISH. This
prevalence is comparable to the relative copy
number changes detected by CGH (Perren et al.
2007) and is slightly lower than the LOH rates
reported using the analysis of microsatellite markers
(Chung et al. 1997, Barghorn et al. 2001), which
might be explained by different sensitivities of the
methods and different cut-off definitions. Interest-
ingly, VHL deletions and VHL promoter methylation
occurred as alternative events in our tumor set.
Summing them up, we describe here nearly 25% of
sporadic PET with genomic VHL alteration, making
this a frequent genetic event in sporadic PET. To
examine whether these alterations really do have an
effect on VHL function, we examined VHL mRNA
expression and a series of downstream targets of
hypoxia signalling.
VHL is part of the E3 ligase marking hydroxylated
HIF1-a for proteasomal degradation (Maxwell et al.
1999, Cockman et al. 2000). Loss of VHL function
or hypoxia, therefore, increases HIF1-a levels, leads to
nuclear translocation, and increases the transcription
of hypoxia-inducible mRNAs and to an upregulation of
several hypoxia response proteins such as CA-9 and
GLUT-1 (Pastorekova et al. 1992, Opavsky et al. 1996,
Loncaster et al. 2001, Hui et al. 2002). Here we show
Figure 4 Kaplan–Meier curve depicting a significant difference
in disease-free survival (DFS) for PET without and with
VHL impairment by deletion or promoter methylation (A).
Kaplan–Meier curve depicting significant difference in disease-
free survival (DFS) for PET immunonegative and for PET
immunopositive for CA-9 (B).
Table 2 Correlations of data obtained from immunohistochemistry, RNA, and DNA analysis
GLUT-1 IHC HIF1-a IHC CA-9 RNA VHL RNA VHL meth VHL LOH VHL mut/meth/del
CA-9 IHC 0.000 0.002 0.000 0.021 0.111 0.000 0.000
GLUT-1 IHC 0.049 0.450 0.128 0.227 0.020 0.156
HIF1-a IHC 0.088 0.010 0.508 0.122 0.220
CA-9 RNA 0.217 1.000 0.039 0.052
VHL RNA 0.083 0.009 0.001
Correlations indicated as P values. Bold type indicates significant correlation.
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for the first time that genomic alterations (deletions or
promoter methylation) of the VHL gene are associated
with a decreased level of VHL transcripts and with
increased nuclear translocation of HIF1 and increased
transcription of the hypoxia-inducible CA-9 RNA and
expression of its protein. Expression of GLUT-1,
another hypoxia-regulated protein, was also associated
with genomic VHL alterations. Interestingly, this
occurred although all tumors only showed either VHL
deletion or promoter methylation. These findings
suggest either VHL haploinsufficiency or another
epigenetic inactivation of the second allele, such as
histone acetylation, for example. Even though this
correlation was statistically significant, the correlation
was not 100%, indicating that other mechanisms than
VHL-impairment might also lead to hypoxia signal-
ling. Couvelard et al. (2005) described a cytoplasmic
CA-9 staining pattern in tumors associated with VHL
disease. In these familial tumors, both VHL alleles are
inactive. In our study, only sporadic PET including
four poorly-differentiated carcinomas (three primary
tumors and one metastasis) were investigated. Nearly
70% of the CA-9 positive tumors in our study showed
both a cytoplasmic and membranous staining pattern
for CA-9 (Fig. 1).
As familial PET in the setting of VHL, NF-1, and
TSC-1 disease have an adverse outcome compared to
MEN1 tumors, we also analyzed the tumor-free
survival of sporadic PET with regard to VHL status
and hypoxia signals. Sporadic PET with genomic VHL
alterations and increased hypoxia signalling were
characterized by an adverse outcome in our series.
We found a more frequent expression of CA-9 in
metastatic PET than in non-metastatic PET (47 vs
16%), similar to previously reported results (Couvelard
et al. 2005) and VHL alterations were found in 21% of
benign and 69% of recurring tumors.
Our results link the upregulation of the HIF-pathway
to alterations of the VHL gene and an adverse outcome
in sporadic tumors. We additionally examined HIF1-a
and the HIF1 downstream target GLUT-1 (Behrooz &
Ismail-Beigi 1999), which were both expressed in
significant correlation with CA-9.
In summary, we show that despite only rare
mutations, the VHL gene is affected by promoter
methylation and most frequently by deletion in
sporadic PET (25%). Monoallelic changes of the
VHL gene are associated with a decreased transcription
and an activation of the HIF-pathway. This leads to an
overexpression of HIF1-a and HIF-targets CA-9 and
GLUT-1 both on mRNA and protein level.
We show that a subset of sporadic PET follows a
genetic pathway similar to the VHL-associated familial
PET and that these tumors have an adverse outcome.
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